Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated ...

Company News Published 05/21/2025, 09:16 AM 0 Alumis completes merger with ACELYRIN, extends cash runway ALMS -0.66% ...

Establishes leading clinical stage biopharma company with differentiated portfolio of therapies and strong balance sheetSOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc ...

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune ...

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune ...

Alumis received an upfront license fee of $20.0 million in March 2025 and will receive an additional $20.0 million in near-term co-development payments, with potential for additional milestone ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing thera ...

Alumis Inc., a clinical-stage biopharmaceutical company focused on therapies for immune-mediated diseases, announced that its stockholders approved all proposals necessary for its merger with ...

Alumis assumes no obligation and does not intend to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Meanwhile, Alumis stockholders will hold about 52% ownership. H.C. Wainwright has recently adjusted its price target for Alumis to $14.00 from $15.00 but maintained a Buy rating following the ...

Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, “We thank our stockholders for their support for the merger and with this milestone now complete, we are moving ...